Latest filings (excl ownership)
S-8
Registration of securities for employees
7 May 24
10-Q
2024 Q1
Quarterly report
2 May 24
8-K
Baxter Reports First-quarter 2024 Results
2 May 24
DEFA14A
Additional proxy soliciting materials
27 Mar 24
DEFA14A
Additional proxy soliciting materials
25 Mar 24
DEF 14A
Definitive proxy
25 Mar 24
8-K
Entry into a Material Definitive Agreement
21 Mar 24
PRE 14A
Preliminary proxy
14 Mar 24
8-K
Regulation FD Disclosure
4 Mar 24
10-K
2023 FY
Annual report
8 Feb 24
8-K
Baxter Reports Fourth-quarter and Full-year 2023 Results
8 Feb 24
10-Q
2023 Q3
Quarterly report
2 Nov 23
8-K
Baxter Reports Third-quarter 2023 Results
2 Nov 23
8-K
Baxter Appoints Joel Grade Chief Financial Officer
3 Oct 23
8-K
Completion of Acquisition or Disposition of Assets
2 Oct 23
8-K
Baxter Announces Updates to Its Board of Directors
21 Aug 23
10-Q
2023 Q2
Quarterly report
27 Jul 23
8-K
Baxter Reports Second-quarter 2023 Results
27 Jul 23
8-K
Regulation FD Disclosure
6 Jul 23
8-K
Baxter Appoints William Ampofo to Its Board
29 Jun 23
SD
Conflict minerals disclosure
31 May 23
8-K
Baxter Signs Definitive Agreement to Divest its BioPharma Solutions Business to
9 May 23
8-K
Submission of Matters to a Vote of Security Holders
4 May 23
10-Q
2023 Q1
Quarterly report
27 Apr 23
8-K
Baxter Reports First-quarter 2023 Results
27 Apr 23
DEFA14A
Additional proxy soliciting materials
23 Mar 23
DEF 14A
Definitive proxy
23 Mar 23
8-K
Entry into a Material Definitive Agreement
13 Mar 23
8-K
Departure of Directors or Certain Officers
14 Feb 23
10-K
2022 FY
Annual report
9 Feb 23
8-K
Baxter Reports Fourth-quarter and Full-year 2022 Results
9 Feb 23
8-K
Baxter Announces Strategic Actions to Enhance Operational Effectiveness, Accelerate Innovation for Patients and Drive Value for Shareholders
6 Jan 23
10-Q
2022 Q3
Quarterly report
27 Oct 22
8-K
Baxter Reports Third-quarter 2022 Results
27 Oct 22
8-K
Entry into a Material Definitive Agreement
30 Sep 22
10-Q
2022 Q2
Quarterly report
28 Jul 22
8-K
Baxter Reports Second-quarter 2022 Results
28 Jul 22
SD
Conflict minerals disclosure
31 May 22
8-K
Baxter Highlights Business Strategies and Innovation
25 May 22
424B3
Prospectus supplement
12 May 22
Latest ownership filings
4
Christopher A. Toth
8 Mar 24
4
Brian Stevens
8 Mar 24
4
Alok Sonig
8 Mar 24
4
David S. Rosenbloom
8 Mar 24
4
Reazur Rasul
8 Mar 24
4
Jeanne K Mason
8 Mar 24
4
James W Borzi
8 Mar 24
4
Heather Knight
8 Mar 24
4
JOSE E ALMEIDA
8 Mar 24
4
Joel T. Grade
8 Mar 24
4
Brian Stevens
6 Mar 24
4
Reazur Rasul
6 Mar 24
4
Heather Knight
6 Mar 24
4
Jeanne K Mason
6 Mar 24
4
James W Borzi
6 Mar 24
4
JOSE E ALMEIDA
6 Mar 24
4
Brian Stevens
5 Mar 24
4
Alok Sonig
5 Mar 24
4
David S. Rosenbloom
5 Mar 24
4
Reazur Rasul
5 Mar 24
4
Jeanne K Mason
5 Mar 24
4
Heather Knight
5 Mar 24
4
James W Borzi
5 Mar 24
4
JOSE E ALMEIDA
5 Mar 24
144
Notice of proposed sale of securities
1 Mar 24
4
Heather Knight
14 Feb 24
3/A
Heather Knight
14 Feb 24
4
Reaz Rasul
14 Feb 24
4
Brian Stevens
14 Feb 24
4
Jeanne K Mason
14 Feb 24
4
James W Borzi
14 Feb 24
4
JOSE E ALMEIDA
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G
DODGE & COX
13 Feb 24
SC 13G/A
BlackRock Inc.
23 Jan 24
4
Joel T. Grade
5 Dec 23
4
Brian Stevens
5 Dec 23
3
Joel T. Grade
19 Oct 23
4
Alok Sonig
6 Sep 23
4
James W Borzi
6 Sep 23